VU 29 - CAS 890764-36-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H16N4O3
Molecular Weight:
384.39
COA:
Inquire
Targets:
mGluR
Description:
VU 29 is a potent positive allosteric potentiator at the rat mGlu5 receptor (EC50 = 9 nM) with selectivity for mGlu5 over mGlu1 and mGlu2 receptors (EC50 = 557 nM and 1.51 μM for mGlu1 and mGlu2, respectively). VU 29 binds to the MPEP allosteric site (Ki app = 244 nM). VU 29 was shown to potentiate both DHPG-induced LTP and threshold θ-burst stimulation (TBS)-induced LTP in rat hippocampal slices.
Publication citing BOC Sciences Products
1. Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival
2. Reactions in Nitroimidazole Triggered by Low‐Energy (0–2 eV) Electrons: Methylation at N1‐H Completely Blocks Reactivity
3. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
4. Isavuconazole and voriconazole inhibition of sterol 14α-demethylases (CYP51) from Aspergillus fumigatus and Homo sapiens
5. Treatment of obesity with celastrol
6. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes

>> More

Brife Description:
positive allosteric potentiator at the rat mGlu5 receptor
Purity:
≥99% by HPLC
Synonyms:
N-(1,3-Diphenyl-1H-pyrazolo-5-yl)-4-nitrobenzamide; DPAP; VU-29; VU 29; VU29; 4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
MSDS:
Inquire
InChIKey:
KIALCSMRIHRFPL-UHFFFAOYSA-N
InChI:
InChI=1S/C22H16N4O3/c27-22(17-11-13-19(14-12-17)26(28)29)23-21-15-20(16-7-3-1-4-8-16)24-25(21)18-9-5-2-6-10-18/h1-15H,(H,23,27)
Canonical SMILES:
C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4
1.Effects of the Positive Allosteric Modulator of Metabotropic Glutamate Receptor 5, VU-29, on Impairment of Novel Object Recognition Induced by Acute Ethanol and Ethanol Withdrawal in Rats.
Marszalek-Grabska M;Gibula-Bruzda E;Bodzon-Kulakowska A;Suder P;Gawel K;Filarowska J;Listos J;Danysz W;Kotlinska JH Neurotox Res. 2018 Apr;33(3):607-620. doi: 10.1007/s12640-017-9857-z. Epub 2018 Jan 2.
Glutamate is essential for learning and memory processes, and acute and chronic exposures to ethanol (or protracted abstinence) alter glutamatergic transmission. In the current study, we investigated the effects of VU-29, positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor, on the acute ethanol- and ethanol withdrawal-induced impairment of novel object recognition (NOR) task in rats. The influence of VU-29 (30 mg/kg) on memory retrieval was measured (a) at 4-h delay after acute ethanol administration, as well as (b) after acute withdrawal (24 and 48 h) of repeated (2.0 g/kg, once daily for 7 days) ethanol administration. Additionally, the effects of VU-29 on expression of mGlu5 and mGlu2 receptor proteins in the hippocampus, prefrontal cortex, and striatum were determined 48 h after ethanol withdrawal. Our results indicated that VU-29, given before acute ethanol administration, prevented the ethanol-induced impairments in spatial memory retrieval. Furthermore, VU-29 given before the testing session on the first day of abstinence facilitated NOR performance in ethanol-withdrawn rats at 4- and 24-h delay after administration. Our ELISA results show that VU-29 normalized ethanol withdrawal induced increase in expression of mGlu5 receptor protein in the hippocampus, prefrontal cortex, and striatum, as well as expression of mGlu2 receptor protein in the hippocampus.
2.Cardiopulmonary effects of combined xylazine-guaiphenesin-ketamine infusion and extradural (inter-coccygeal lidocaine) anaesthesia in calves.
Picavet MT;Gasthuys FM;Laevens HH;Watts SA Vet Anaesth Analg. 2004 Jan;31(1):11-9.
OBJECTIVE: ;To investigate the cardiopulmonary effects of a xylazine-guaiphenesin-ketamine infusion combined with inter-coccygeal extradural (lidocaine) anaesthesia in calves.;STUDY DESIGN: ;Prospective study.;ANIMALS: ;Five Holstein Friesian calves (one steer, four heifers) aged 6 weeks weighing 65.2 +/- 2.7 kg.;MATERIALS AND METHODS: ;Calves were anaesthetized with isoflurane in oxygen for instrumentation. At least 12 hours later, xylazine (0.2 mg kg(-1) i.m.) was given. After 15 minutes, an infusion of xylazine hydrochloride (0.1 mg mL(-1)), guaiphenesin (50 mg mL(-1)) and ketamine (1 mg mL(-1)) (X-G-K) was infused at a rate of 1.1 mL kg(-1) hour-1 i.v. Oxygen (4 L minute(-1)) was delivered by nasotracheal tube 30 minutes later. Inter-coccygeal (Co1-Co2) extradural anaesthesia (lidocaine 2%, 0.18 mL kg(-1)) was administered 30 minutes later. Cardiopulmonary variables were obtained in the unsedated standing calves 10 minutes after xylazine, 15 and 30 minutes after X-G-K without O2, 15 and 30 minutes after X-G-K with O2 and 5, 15, 30, 45 and 60 minutes after extradural anaesthesia. Data were analysed using a repeated measurement analysis of variance including an autoregressive covariance structure of order 1 (correlations at different time intervals).
3.[Cardiovascular effects of a single dose of propofol in coronary patients with good ventricular function].
Pensado A;Molins N;Alvarez J Rev Esp Anestesiol Reanim. 1994 May-Jun;41(3):147-51.
OBJECTIVES: ;To determine the cardiovascular effects of a single dose of propofol in coronary patients with good ventricular function.;PATIENTS AND METHODS: ;Propofol 2 mg/kg-1 was administered to twenty coronary patients during dissection of the internal mammary artery in myocardial revascularization surgery. Heart rate (HR), systolic and diastolic systemic and pulmonary arterial pressure (SAP, DAP, SPAP and DPAP), central venous pressure, pulmonary capillary wedge pressure, cardiac output (CO), right ventricular ejection fraction, systemic and pulmonary vascular resistances (SVR and PVR), right and left ventricular stroke work index (RVSWI and LVSWI), rate-pressure product (RPP) and pressure-rate quotient (PRQ) were recorded prior to (baseline) and at 1, 3, 5, 10, 15, 20 and 30 min after administration of the drug.;RESULTS: ;One minute after administration of the drug there was a maximum decrease in SAP (-26%), DAP (-17%), SVR (-22%), RVSWI (-23%), RPP (-24%) and PRQ (-22%) (p < 0.001 in all cases) and this continued to be significant throughout the study for SAP, DAP and RPP, and for SVR, RVSWI and PRQ at times 15, 3 and 10, respectively. There were no significant changes in HR, CO, ventricular filling pressures and the remaining variables during the study.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products

CAS 327056-22-4 VU 0285683

VU 0285683
(CAS: 327056-22-4)

VU 0285683 is a negative allosteric modulator of mGlu5 receptors with high affinity for the MPEP binding site. VU 0285683 exhibits anxiolytic activity in rodent...

CAS 327056-26-8 AZD 9272

AZD 9272
(CAS: 327056-26-8)

AZD 9272 is a potent, long-acting and selective nervous system penetrant mGlu5 antagonist with IC50 values of 2.6 and 7.6 nM for rat and human receptors, respec...

CAS 802906-73-6 RG7090

RG7090
(CAS: 802906-73-6)

RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).

(±)-ADX 71743
(CAS: 1431641-29-0)

(±)-ADX 71743 has been found to be a negative allosteric modulator at mGlu7 and is brain penetrant.

CAS 338736-46-2 LY 456236 hydrochloride

LY 456236 hydrochloride
(CAS: 338736-46-2)

LY 456236 hydrochloride is a mGlu1 receptor antagonist with IC50 value of 143 nM. It may be used in the treatment of chronic pain.

CAS 2018282-44-3 BMT-145027

BMT-145027
(CAS: 2018282-44-3)

BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy.

CAS 1127498-03-6 JNJ-40411813

JNJ-40411813
(CAS: 1127498-03-6)

JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.

CAS 606-59-7 Cinnabarinic acid

Cinnabarinic acid
(CAS: 606-59-7)

Cinnabarinic acid is a kynurenine pathway metabolite of tryptophan and is produced by the oxidation of 3-Hydroxyanthranilic acid. It is a metabotropic glutamate...

Chemical Structure

CAS 890764-36-0 VU 29

Quick Inquiry

Verification code

Featured Items